|
1
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pasechnikov V, Chukov S, Fedorov E,
Kikuste I and Leja M: Gastric cancer: Prevention, screening and
early diagnosis. World J Gastroenterol. 20:13842–13862. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
CancerGenome Atlas Research Network;
AnalysisWorking Group: Asan University; BC Cancer Agency; Brigham
and Women's Hospital; Broad Institute; Brown University; Case
Western Reserve University; Dana-Farber Cancer Institute; Duke
University, et al, . Integrated genomic characterization of
oesophageal carcinoma. Nature. 541:169–175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moro K, Nagahashi M, Naito T, Nagai Y,
Katada T, Minagawa M, Hasegawa J, Tani T, Shimakage N, Usuda H, et
al: Gastric adenosquamous carcinoma producing granulocyte-colony
stimulating factor: A case of a rare malignancy. Surg Case Rep.
3:672017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsuda T and Saika K: The 5-year relative
survival rate of stomach cancer in the USA, Europe and Japan. Jpn J
Clin Oncol. 43:1157–1158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lewis SA, Lee MG and Cowan NJ: Five mouse
tubulin isotypes and their regulated expression during development.
J Cell Biol. 101:852–861. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang YL, Luo XP and Xian L: The prognostic
role of the class III β-tubulin in non-small cell lung cancer
(NSCLC) patients receiving the taxane/vinorebine-based
chemotherapy: A meta-analysis. PLoS One. 9:e939972014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hinsch A, Chaker A, Burdelski C, Koop C,
Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer
C, et al: βIII-tubulin overexpression is linked to aggressive tumor
features and genetic instability in urinary bladder cancer. Hum
Pathol. 61:210–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lebok P, Öztürk M, Heilenkotter U,
Jaenicke F, Müller V, Paluchowski P, Geist S, Wilke C, Burandt E,
Lebeau A, et al: High levels of class III β-tubulin expression are
associated with aggressive tumor features in breast cancer. Oncol
Lett. 11:1987–1994. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kavallaris M, Kuo DY, Burkhart CA, Regl
DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial
ovarian tumors are associated with altered expression of specific
beta-tubulin isotypes. J Clin Invest. 100:1282–1293. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ranganathan S, Benetatos CA, Colarusso PJ,
Dexter DW and Hudes GR: Altered beta-tubulin isotype expression in
paclitaxel-resistant human prostate carcinoma cells. Br J Cancer.
77:562–566. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hwang JE, Hong JY, Kim K, Kim SH, Choi WY,
Kim MJ, Jung SH, Shim HJ, Bae WK, Hwang EC, et al: Class III
β-tubulin is a predictive marker for taxane-based chemotherapy in
recurrent and metastatic gastric cancer. BMC Cancer. 13:4312013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao Y, Zhang G, Wang P, Zhou J, Gan W,
Song Y, Huang L, Zhang Y, Luo G, Gong J and Zhang L: Clinical
significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1,
TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC
Gastroenterol. 17:22017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu Y, Ding S, Liang Y, Zheng Y, Li W, Yang
L, Zheng X and Jiang J: Expression of ERCC1, TYMS, TUBB3, RRM1 and
TOP2A in patients with esophageal squamous cell carcinoma: A
hierarchical clustering analysis. Exp Ther Med. 7:1578–1582. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burkhart CA, Kavallaris M and Band Horwitz
S: The role of beta-tubulin isotypes in resistance to antimitotic
drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI
|
|
16
|
Brierley JD, Gospodarowicz MK and
Wittekind C: UICC TNM Classification of Malignant Tumours. 8th
edition. Wiley Blackwell; New York, NY: 2017
|
|
17
|
Kononen J, Bubendorf L, Kallioniemi A,
Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G
and Kallioniemi OP: Tissue microarrays for high-throughput
molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mirlacher M and Simon R: Recipient block
TMA technique. Methods Mol Biol. 664:37–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Urano N, Fujiwara Y, Doki Y, Kim SJ,
Miyoshi Y, Noguchi S, Miyata H, Takiguchi S, Yasuda T, Yano M and
Monden M: Clinical significance of class III beta-tubulin
expression and its predictive value for resistance to
docetaxel-based chemotherapy in gastric cancer. Int J Oncol.
28:375–381. 2006.PubMed/NCBI
|
|
20
|
Nair KS, Naidoo R and Chetty R:
Microsatellite analysis of the APC gene and immunoexpression of
E-cadherin, catenin and tubulin in esophageal squamous cell
carcinoma. Hum Pathol. 37:125–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schlomm T, Iwers L, Kirstein P, Jessen B,
Köllermann J, Minner S, Passow-Drolet A, Mirlacher M,
Milde-Langosch K, Graefen M, et al: Clinical significance of p53
alterations in surgically treated prostate cancers. Mod Pathol.
21:1371–1378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Panda D, Miller HP, Banerjee A, Ludueña RF
and Wilson L: Microtubule dynamics in vitro are regulated by the
tubulin isotype composition. Proc Natl Acad Sci USA.
91:11358–11362. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Falconer MM, Echeverri CJ and Brown DL:
Differential sorting of beta tubulin isotypes into
colchicine-stable microtubules during neuronal and muscle
differentiation of embryonal carcinoma cells. Cell Motil
Cytoskeleton. 21:313–325. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsourlakis MC, Weigand P, Grupp K, Kluth
M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T,
et al: βIII-tubulin overexpression is an independent predictor of
prostate cancer progression tightly linked to ERG fusion status and
PTEN deletion. Am J Pathol. 184:609–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Horak CE, Pusztai L, Xing G, Trifan OC,
Saura C, Tseng LM, Chan S, Welcher R and Liu D: Biomarker analysis
of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone
or Paclitaxel in early-stage breast cancer. Clin Cancer Res.
19:1587–1595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Levallet G, Bergot E, Antoine M, Creveuil
C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet
J, Morin F, et al: High TUBB3 expression, an independent prognostic
marker in patients with early non-small cell lung cancer treated by
preoperative chemotherapy, is regulated by K-Ras signaling pathway.
Mol Cancer Ther. 11:1203–1213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng
CM and Zhou XW: Association between class III β-tubulin expression
and response to paclitaxel/vinorebine-based chemotherapy for
non-small cell lung cancer: a meta-analysis. Lung Cancer. 77:9–15.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Katsetos CD, Herman MM and Mörk SJ: Class
III beta-tubulin in human development and cancer. Cell Motil
Cytoskeleton. 55:77–96. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao S, Zhao X, Lin B, Hu Z, Yan L and Gao
J: Clinical implications of REST and TUBB3 in ovarian cancer and
its relationship to paclitaxel resistance. Tumour Biol.
33:1759–1765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carrara L, Guzzo F, Roque DM, Bellone S,
Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ and
Santin AD: Differential in vitro sensitivity to patupilone versus
paclitaxel in uterine and ovarian carcinosarcoma cell lines is
linked to tubulin-beta-III expression. Gynecol Oncol. 125:231–236.
2012. View Article : Google Scholar : PubMed/NCBI
|
